Navigation Links
Study shows new treatment strategy effective for certain lung cancers
Date:3/10/2011

New Orleans, LA LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients. Dr. Cataldo, a Clinical Assistant Professor of Medicine at LSU Health Sciences Center New Orleans School of Medicine, practicing at LSU's Earl K. Long Medical Center and Hematology-Oncology Clinic in Baton Rouge, and his colleagues say these drugs should be considered as a first-line treatment in people who are known to carry an Epidermal Growth Factor Receptor (EGFR) mutation. The paper is published in the March 10, 2011 issue of the New England Journal of Medicine.

The drugs, Erlotinib and Gefitinib, which are in a class of highly-specific small molecule tyrosine kinase inhibitors, work by blocking the activation of EGFR which is involved in cell survival and growth, as well as the development of a nourishing blood supply and metastasis.

"Targeting the genetic mutation contributing to the development of the cancer, this class of drugs produced a response rate that exceeded 70% in these patients," notes Dr. Cataldo.

The drugs, taken by mouth, also had fewer side effects. Unlike traditional cytotoxic agents, Erlotinib and Gefitinib do not typically cause myelosuppression, neuropathy, alopecia, or severe nausea.

Lung cancer, the leading cause of cancer-related death worldwide, accounted for an estimated 157,300 deaths in the United States in 2010. Approximately 85 to 90% of all cases of lung cancer are nonsmall-cell lung cancer (NSCLC) which is also associated with smoking. Advanced-stage NSCLC is currently considered an incurable disease for which standard chemotherapy provides marginal improvement in overall survival at the expense of substantial morbidity and mortality. Furthermore, less than 30% of patients with meta
'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study finds usage of, recommendations for supplements common within various physician specialties
2. Study provides explanation for connection between low birth weight and obesity later in life
3. New UF study shows some sharks follow mental map to navigate seas
4. Study shows how plants sort and eliminate genes over millennia
5. MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea
6. Rensselaer professor utilizing New York state grant to study adult stem cells
7. Study analyzes role of PARP enzyme in eukaryotes
8. Fossil bird study describes ripple effect of extinction in animal kingdom
9. University of Missouri researcher study provides insight into how corn makes hormones
10. Rainwater harvest study finds roofing material affects water quality
11. A study reveals the keys to the locomotion of snails
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... people regain strength and normal use of affected hands ... California, Irvine study. , Stroke patients with ... release objects after therapy sessions using the Hand-Wrist Assisting ... residual weakness and reduced function of the right hand, ...
... The results of a new study suggest that bacteria ... illness can turn the genes that make them infectious ... Yersinia pestis and E. coli, do this may one ... of these genes, thereby making the bacteria harmless, said ...
... than what scientists had been assuming. A new study, appearing ... Chemistry, provides new information on the inner workings of cells ... make livers regrow in patients with liver diseases such as ... one of the few organs in the body that can ...
Cached Biology News:Robotic therapy helps restore hand use after stroke 2Robotic therapy helps restore hand use after stroke 3Bacteria control how infectious they become, study finds 2Bacteria control how infectious they become, study finds 3Liver regeneration may be simpler than previously thought 2Liver regeneration may be simpler than previously thought 3
(Date:7/25/2015)... , ... July 25, 2015 , ... ... its refractometer series. It precisely checks and adjusts the surface temperature of the ... , In the pharmaceutical industry, data traceability and documentation are key requirements. It ...
(Date:7/24/2015)... 2015 Equity Research Institute has ... (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ... Biotherapeutics Inc. (NASDAQ: NWBO ), and Acorda Therapeutics ... PDL BioPharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI ... at 5,146.41, down 0.49%, the Dow Jones Industrial Average ...
(Date:7/24/2015)... BEIJING , July 24, 2015 Origin Agritech ... supplier of crop seeds in China , ... third quarter fiscal year 2015 ended June 30, 2015, before ... The Company will host a teleconference on August 5th, 2015, ... time to discuss the results. To participate in ...
(Date:7/24/2015)... , ... July 24, 2015 ... ... class-leading frozen sample management solution, indispensable to any modern scientific or pharmaceutical ... has a user-friendly interface. Users know precisely where a sample is located ...
Breaking Biology Technology:It’s T-Time for Refractometers: On-site Temperature Check Now Available 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4
... In Lawsuit, CHICAGO, May 14 Last month ... on behalf of Davenport,Iowa resident, Mark Scott who suffered ... 30, 2007. The complaint was filed On April 1, ... Law Group and alleges that,Melissa Scott,s untimely death was ...
... Also Augments Senior Management Team with Recent Strategic Hires ... ... Rico, May 14 Triple-S,Management Corporation (NYSE: GTS ) today announced ... investigator for the Children,s Oncology Group and,the Dana Farber Acute Lymphoblastic Leukemia ...
... Ill., May 14 Sagent Pharmaceuticals, Inc.,a privately-held ... US$20,000 to the American Red Cross to assist ... "As a part of the global community, we ... of the Sichuan province," said Jeffrey M. Yordon,chief ...
Cached Biology Technology:Iowa Resident Dies After Using Contaminated Blood Thinner 2Iowa Resident Dies After Using Contaminated Blood Thinner 3Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director 2
mCD-1 10 transcription reactions...
Recombinant Rhesus Macaque IFN-alpha...
... 500 g protein ... mouse whole cell lysate; Abelson transformed ... provided as Western blotting positive control, ... freezing and thawing should be minimized, ...
The epitope is specific for TASK and is not present in any other known proteins tested so far.,SPECIES REACTIVITIES: The epitope is also highly conserved between mouse and rat (17/18 residues iden...
Biology Products: